PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084734
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2084734
Asia Pacific Generic Oncology Sterile Injectable Market, By Drug Type, By Disease Indication, By Distribution Channel, By Geography
Asia Pacific Generic Oncology Sterile Injectable Market is estimated to be valued at USD 17.5 Bn in 2026 and is expected to reach USD 27.3 Bn by 2033, growing at a compound annual growth rate (CAGR) of 13.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 17.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.10% | 2033 Value Projection: | USD 27.3 Bn |
Generic oncology sterile injectables are used for the treatment of various types of cancers such as ovarian, breast, and lung. Generic oncology sterile injectable products are relatively cheaper than branded counterparts. Treatment cost is a major concern for cancer patients, especially in emerging economies such as India and China. Therefore, governments of such countries are focusing on reducing the cost of medications and increasing its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of a few cancer products by 86% in March 2017.
Market Dynamics
Various India-based pharmaceutical companies are intended towards expansion of their distribution globally, leading to the generation of significant revenue which will aid in growth of generic oncology sterile injectables market in the region. For instance, in July 2017, Alembic Pharmaceuticals, an India-based company, inaugurated its manufacturing facility for generic oncology products in Gujarat that will cater to the markets in the Middle East, Africa, Asia, and North America. The manufacturing site has a capacity for 60 million tablets and capsules, and around 20 million vials capacity for liquid injectable and lyophilized products.
Similarly, in 2016, Sun Pharma expanded the company's presence in Japan with the acquisition of 14 prescribed brands from Novartis for US$ 293 Mn.
Furthermore, Lupin, a pharmaceutical Indian firm active in Japan, announced in February 2016 that its subsidiary Kyowa is setting up a manufacturing plant in Tottori, to meet the rising demand for generics in Japan, where generics represent 49% of drug sales volume marking the second-largest drug market, after the U.S., in the world.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the Asia Pacific generic oncology sterile injectable market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Eli Lily and Company, Biocon Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd, Baxter International Inc., Hikma Pharmaceuticals, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The Asia Pacific generic oncology sterile injectable market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the Asia Pacific generic oncology sterile injectable market
Market Segmentation
- By Drug Type (Revenue, USD Bn, 2021-2033)
- Monoclonal Antibodies
- Chemotherapy
- Alkylating Agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Cytokines
- Peptide Hormones
- By Disease Indication (Revenue, USD Bn, 2021-2033)
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Key Players
- Eli Lily and Company
- Biocon Ltd.
- Sun Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd
- Baxter International Inc.
- Hikma Pharmaceuticals
- Mylan N.V.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Industry Trends
- Pipeline Analysis
- Patent Expiry
- Product Launch/ Approval
- Mergers And Acquisition Scenario
- Regulatory Scenario
- PEST Analysis
4. Asia Pacific Generic Oncology Sterile Injectable Market, By Drug Type, 2021-2033 (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Alkylating Agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Peptide Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Asia Pacific Generic Oncology Sterile Injectable Market, By Disease Indication, 2021-2033 (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pancreatic Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Asia Pacific Generic Oncology Sterile Injectable Market, By Distribution Channel, 2021-2033 (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Asia Pacific Generic Oncology Sterile Injectable Market, By Country, 2021-2033 (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022 - 2033
- Regional Trends
- China
- Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
- India
- Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
- Japan
- Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
- Australia
- Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
- South Korea
- Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
- ASEAN
- Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
- Rest of Asia Pacific
- Market Size and Forecast, By Drug Type, 2021-2033 (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021-2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Bn)
8. Competitive Landscape
- Company Profiles
- Eli Lily and Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Biocon Ltd.
- Sun Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd
- Baxter International Inc.
- Hikma Pharmaceuticals
- Mylan N.V.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Eli Lily and Company
9. Section
- Research Methodology
- About us
- Contact
